EVENTS CALENDAR 2021
Randox Events Calendar
After what has been an unprecedented year of travel restrictions due to the global pandemic, we look forward to slowly transitioning back to business as usual – or in some cases the new ‘virtual’ normal!
Whether it’s face-to-face or digital attendance from the comfort of the office, Randox have a wealth of new products and innovative technologies to share with the industry. Check out below what events Randox will be attending this year. We hope to see you there!
EVENT: Medlab Middle East, 2021
DATES: Live 21-24 June 2021 / Online 23 May – 22 July 2021
Randox are attending the live show at the Dubai World Trade Centre on 21-24 June 2021. If you are unable to attend we are showcasing all of our latest product portfolio and services virtually online, starting on 23 May – 22 July 2021.
EVENT: Goodwood Revival, 2021
DATES: 17-19 Sept 2021
Randox are attending Goodwood Revival to celebrate bygone days, vintage fashion and motor racing around the classic circuit, but that’s not all! Randox will be casting a light on all the latest technologies in Clinical Diagnostics to showcase just how far we have come in helping to improve global health worldwide. More details coming soon so stayed tuned.
DATES: Online 7, 13, 15, 20, 22 July 2021
Visit our virtual stand for stimulating educational content, webinars, abstracts and networking opportunities. Heart UK are offering reduced registration fees and with no travel costs all that is required is your time.
Benefits of the Randox 5th Generation Bile Acids Assay
Utilising the advanced enzyme cycling method, the Randox 5th generation bile acids assay displayed outstanding sensitivity and precision when compared to the traditional enzymatic based tests.
Excellent measuring range
The Randox 5th generation bile acids assay has a measuring range of 2.16 – 238µmol/l for the comfortable detection of clinically important results.
A correlation coefficient of r=0.99 was displayed when the Randox method was compared against other commercially available methods.
The Randox 5th generation bile acids is available in a liquid ready-to-use format for convenience and ease-of-use.
Calibrator and controls available
Calibrator and controls are available offering a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox 5th generation bile acids assay on a variety of clinical chemistry analysers.
A 4th generation method for bile acids testing is also available which offers an excellent linearity up to 150µmol/l. Applications available detailing instrument-specific settings for the convenient use of the Randox 4th generation bile acids assay on a variety of clinical chemistry analysers.
Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is a pregnancy-specific liver disorder. ICP, characterised by maternal pruritus in the absence of a rash and increased total bile acids (TBA) levels, is a severe form, yet reversible, cholestasis commonly occurring in the second and third trimester of pregnancy. Diagnostic and therapeutic guidelines are lacking for ICP which is of concern as ICP can have significant foetal risks 1, 2.
ICP restricts the flow of bile through the gallbladder causing bile acids to build-up in the liver 2. Due to the build-up, bile acids leak into the bloodstream where they are detected at concerning levels. It has been documented that TBA levels in ICP can reach as high as 100 times the upper limit of a normal pregnancy. Moreover, a doubling in maternal serum TBA levels, results in a 200% increased risk of stillbirth. Additionally, elevated serum bile acids can affect the foetal cardiovascular system causing issues such as cardiac rhythm disturbances 3.
Whilst other liver function tests exist, including: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) and bilirubin; TBA testing is thought to be the most beneficial method for the diagnosis and monitoring ICP. Moreover, TBA measurements are believed to be the most beneficial when tested in conjunction with standard liver tests, offering unrivalled sensitivity enabling the identification of early stage hepatic dysfunction 3.
The enzyme cycling method enables signal amplification through cycled regeneration reactions. In the presence of Thio-NAD, the enzyme 3-α hydroxysteroid dehydrogenase (3-α HSD) converts bile acids to 3-keto steroids and Thio-NADH (Fig. 1). The reaction is reversible and 3-α HSD can convert 3-keto steroids and Thio-NADH to bile acids and Thio-NAD. In the presence of excess NADH, the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is determined by measuring specific change of absorbance at 405nm 5.
Fig 1: Enzyme cycling assay principle 5
Want to know more?
Contact us or download the Total Bile Acids Whitepaper.
Clinical Chemistry Calibrator
Clinical Chemistry Control
Clinical Chemistry EQA
Reagents Resource Hub
 Ambros-Rudolph CM, Glatz M, Trauner M, Kerl H, Müllegger RR. The Importance of Serum Bile Acid Level Analysis and Treatment With Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy. Journal of the American Medical Association (JAMA) 2007; (): https://jamanetwork.com/journals/jamadermatology/fullarticle/413291 (accessed 10 February 2020).
Featured Reagent | Cystatin C
Kidney disease is a huge global health crisis, increasing healthcare costs, mortality and morbidity rates. The global prevalence of chronic kidney disease (CKD) has continued to rise during a short lifespan. In 2016, 1 in 10, equivalent to 10 percent of the global population were identified with having CKD with the highest prevalence’s reported in Europe, the Middle East, East Asia and Latin America, estimated at 12 per cent and the lowest in South Asia, estimated at 7 percent1.
The early risk assessment of renal function is vital. In 1990, CKD was ranked the 27th leading cause of death in the Global Burden of Disease study2, rising to 18th 3 in 2010, 13th in 20132 and 12th by 2015. From 2005-2015, the overall CKD mortality rate has risen by 31.7 percent, accounting for 1.1 million deaths globally in 20154.
Inadequacies of Traditional CKD Biomarkers
The most commonly used screening test for renal impairment is creatinine. When testing for CKD using creatinine, certain factors must be taken into consideration, including: age, gender, ethnicity, and muscle mass. As such, black men and black women will present with higher creatinine levels compared to white men and white women respectively5.
Serum creatinine is not an adequate screening test for renal impairment in the elderly (65 years of age and over) due to their decreased muscle mass. As such, patients are misdiagnosed, thus, patients with severe renal failure are receiving suboptimal care6.
The main disadvantage of using creatinine to screen for renal impairment is that up to 50 percent of renal function can be lost before significant creatinine levels become detectable as creatinine is insensitive to small changes in the glomerular filtration rate (GFR). Consequently, treatment is not provided at the appropriate time which can be fatal, thus, an earlier and more sensitive biomarker for renal function is vital7.
Cystatin C is a small (13 kDa) cysteine proteinase inhibitor, produced by all nucleated cells at a constant rate. Cystatin C travels through the bloodstream to the kidneys where it is freely filtered by the glomerular membrane, resorbed and fully catabolised by the proximal renal tubes. Consequently, cystatin C is the ideal biomarker of GFR function8.
Clinical Significance of Cystatin C
The National Institute for Health and Care Excellence (NICE) (2014) guidelines recommend cystatin C testing due to its higher specificity for significant disease outcomes than those based on creatinine. As such, eGFR cystatin C measurements will significantly reduce the number of misdiagnosed patients, thus reducing the overall CKD burden9.
In 2017, a systematic literature search found 3,500 investigations into cystatin C as a marker of GFR. The study concluded that eGFRcystatinc was a significantly more superior than eGFRcreatinine10.
Benefits of Cystatin C
The Randox cystatin C assay utilises the latex enhanced immunoturbidimetric method offering numerous key features:
A niche product from Randox meaning that Randox are one of the only manufacturers to provide the cystatin C test in an automated biochemistry format
An automated assay which removes the inconvenience and time consumption associated with traditional ELISA testing
Applications are available detailing instrument-specific settings for the convenient use of the Randox cystatin C assay on a wide range of biochemistry analysers
Liquid ready-to-use reagents for convenience and ease-of-use
Latex enhanced immunoturbidimetric method delivering high performance
Extensive measuring range for the detection of clinically important results
Complementary controls and calibrators available offering a complete testing package
Limited interference from Bilirubin, Haemoglobin, Intralipid® and Triglycerides
Cystatin C does not suffer from a ‘blind area’ like creatinine due to cystatin C’s sensitivity to small changes in GFR enabling the early detection renal impairment
An exceptional correlation coefficient of r=1.00 when compared against standard methods
 Bello, AK, et al. Global Kidney Health Atlas: A report by the Internal Society of Nephrology on the current state of organization and structures for kidney care across the globe. Brussels : Internal Society of Nephrology, 2017.
 Bikbov, Boris. Chronic kidney disease: impact on the global burden of mortality and morbidity. The Lancet. [Online] 2015. http://www.thelancet.com/campaigns/kidney/updates/chronic-kidney-disease-impact-on-global-burden-of-mortality-and-morbidity.
 National Kidney Foundation. Global Facts: About Kidney Disease. National Kidney Foundation. [Online] National Kidney Foundation, 2015. https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease#_ENREF_1.
 Neuen, Brendon Lange, et al. Chronic kidney disease and the global NCDs agenda. s.l. : BMJ Global Health, 2017.
 Lascano, Martin E and Poggio, Emilio D. Kidney Function Assessment by Creatinine-Based Estimation Equations. Cleveland Clinic. [Online] August 2010. [Cited: May 16, 2018.] http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/kidney-function/.
 Swedko, Peter J, et al. Serum Creatinine Is an Inadequate Screening Test for Renal Failure in Elderly Patients. Research Gate. [Online] February 2003. [Cited: May 6, 2018.] https://www.researchgate.net/publication/8243393_Serum_Creatinine_Is_an_Inadequate_Screening_Test_for_Renal_Failure_in_Elderly_Patients.
 Mishra, Umashankar. New technique developed to detect chronic kidney disease. Business Line. [Online] May 07, 2018. [Cited: May 17, 2018.] https://www.thehindubusinessline.com/news/science/new-technique-to-detect-chronic-kidney-disease/article23803316.ece.
 Chew, Janice SC, et al. Cystatin C-A Paradigm of Evidence Based Laboratory Medicine. NCBI. [Online] May 29, 2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533150/.
 National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management: 2 Implementation: getting started. NICE. [Online] January 2015. [Cited: April 19, 2018.] https://www.nice.org.uk/guidance/cg182/chapter/implementation-getting-started.
 Grubb, Anders. Cystatin C is Indispensable for Evaluation of Kidney Disease. NCBI. [Online] December 28, 2017. [Cited: April 19, 2018.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746836/.
MORE FEATURED REAGENTS
For more featured reagents click VISIT
Superoxide Dismutase (Ransod)
Benefits of the Randox Ransod Assay
A correlation coefficient of r=0.965 was displayed when the Randox Ransod assay was compared against commercially available methods.
The Randox Ransod assay displayed a within run precision of <4.65% CV.
Excellent measuring range
The Randox Ransod assay has a measuring range of 0.06 – 4.52U/ml for the comfortable detection of clinically important results.
Standard included in kit
The standard is supplied with the Ransod kit, simplifying the ordering process.
Dedicated Ransod control available
A dedicated Ransod control is available offering a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox Ransod assay on a variety of clinical chemistry analysers.
Superoxide dismutase (SOD) are a group of metalloenzymes, the first line of defence against reactive oxygen species (ROS)-medicated injury. SOD is responsible for catalysing the dismutation of the superoxide anion free radical (O2–) into molecular oxygen and hydrogen peroxide (H2O2). The aim of this process is to reduce the levels of O2– as it damages cells at excessive concentrations 1.
SOD is the most important antioxidant defence against oxidative stress. SOD is a severe anti-inflammatory agent and can prevent precancerous cell changes. Reduced SOD levels have been observed in older generations as SOD levels drop as the body ages and so are more prone to oxidative related diseases. Reduced SOD activity has been identified as having a strong correlation with Alzheimer’s Disease. The overexpression of SOD-2 reduces hippocampal superoxide, preventing memory defects 1. Moreover, SOD has been identified as a potential diagnostic and prognostic marker in patients with gastric cancer 2. SOD has also been linked to other health conditions, including: rheumatoid arthritis, RBC-related disorders, Crohn’s Disease, cystic fibrosis, malignant breast cancer and neuronal apoptosis 1, 3.
Fig. 1. Pathological effects associated with SOD gene mutation or SOD deficiency 4
Reagents Resource Hub
 Li J, Lei J, He L, Fan X, Yi F, et al. Evaluation and Monitoring of Superoxide Dismutase (SOD) Activity and its Clinical Significance in Gastric Cancer: A Systematic Review and Meta-Analysis. Medical Science Monitor 2019; 19(25): 2032-2042.
 Marrocco I, Altieri F, Peluso I. Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. Oxidative Medicine and Cellular Longevity 2017; 2017(6501046): 1-32. http://downloads.hindawi.com/journals/omcl/2017/6501046.pdf (accessed 25 February 2020).
 Ighodaro OM, Akinloye. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria Journal of Medicine 2018; 54(4): 287-293.
Reagent | Aldolase
A Myositis Biomarker
Benefits of the Randox Aldolase Assay
A correlation coefficient of r=0.9917 was displayed when the Randox methodology was compared against commercially available methods.
Excellent measuring range
The Randox aldolase assay has a measuring range of 1.73 – 106U/l for the comfortable detection of clinically important results.
Lyophilised reagents offer enhanced stability, reducing wastage.
The Randox assay displayed a within run precision < 4.47% CV.
Dedicated calibrator and controls available
Randox offer a dedicated aldolase calibrator and controls for a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox aldolase assay on a variety of clinical chemistry analysers.
Elevated levels of aldolase are detected in myotonic muscular disease, including: polymyositis and progressive muscular dystrophy. Elevated levels of this enzyme have been observed in acute coronary syndromes 1. This enzyme has been identified as a myositis biomarker, a muscle-wasting disease resulting in reduced muscle strength and fatigue 2. Testing this enzyme can be utilised as a marker in the differential diagnosis of muscle weakness as aldolase levels remain consistent where weakness is caused by neurological problems such as multiple sclerosis (MS) 3.
Aldolase is a glycolytic enzyme responsible for catalysing the conversion of fructose 1-6-diphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate via the glycolysis metabolic pathway. This enzyme is present in all bodily cells, more commonly in the nucleus and cytoplasm. It has been identified as having three isoforms: A, B and C. Isoform A is found bound to the actin-containing filament of the cytoskeleton. By binding (reversible) to these filaments, aldolase aids in regulating cell contractions. The highest concentrations of this enzyme are present in the brain, liver and muscles 1.
A-Z Randox Reagents
 Berridge BR, Van Vleet JF, Herman E. Cardiac, Vascular, and Skeletal Muscle Systems. Haschek WM, Rousseaux CG, Wallig MA (eds). Haschek and Rousseaux’s Handbook of Toxicologic Pathology, 3rd ed. Academic Press; 2013. pp. 1567-1665
 The Myositis Association. About Myositis. https://www.myositis.org/about-myositis/ (accessed 27 February 2020)
 The Myositis Association. Blood Tests. https://www.myositis.org/about-myositis/diagnosis/blood-tests/ (accessed 27 February 2020).
Reagent | Anti-Streptolysin O (ASO)
Key benefits of the Anti-Streptolysin O reagent
Excellent correlation to standard methods
The Randox Anti-Streptolysin O assay showed an excellent correlation coefficient of 0.97 compared against other commercially available methods.
Stable until expiry date when stored at +2 to +8°C
The antiserum of Randox Anti-Streptolysin O is monospecific for human ASO and has not been shown to cross react with other serum proteins.
Available in a liquid ready-to-use format for convenience and ease-of-use.
Applications available detailing instrument-specific settings for the convenient use of the Randox albumin assay on a variety of clinical chemistry analysers.
The Randox assay displays a measuring range 28 – 1314 IU/ml
What is the Anti-Streptolysin O (ASO) assay used for?
What is Anti-Streptolysin O (ASO)?
Streptolysin O (SLO) is a toxic and lethal, exocellular immunogenic protein produced and released in response to Group A Streptococcal pyogenes. For more information on streptococcal infections, please click here [external link]. The release of SLO stimulates the production of Anti-Streptolysin O (ASO) antibodies to neutralise the SLO’s haemolytic effects. The O in the name stands for oxygen-labile.
What is the Anti-Streptolysin O (ASO) assay used for?
The Anti-Streptolysin (ASO) test is used to determine recent streptococcal infection and post streptococcal complications which includes rheumatic fever and glomerulonephritis. The presence and level of ASO antibodies in human serum directly reflects the extent and degree of infection. Elevated levels of ASO may also be present in other conditions including scarlet fever, acute rheumatoid arthritis, tonsillitis and various other streptococcal infections as well as in health carriers.
The Randox Anti-Streptolysin (ASO) assay is used to measure the presence of anti-streptolysin antibodies in the blood to determine if a strep infection is present.
Why Choose Randox Antioxidants Reagents?
The Randox range of antioxidant reagents are designed for use within a variety of sectors including clinical, research, veterinary, pharma, food and beverages, cosmetics and sports. Furthermore, our range of antioxidant reagents include routine antioxidant reagents, as well as more specialised tests that are unique to Randox.
Randox Antioxidant Reagents Benefits
The role of antioxidant reagents
Antioxidants are important for the body’s immune system to protect the body against free radical attacks. Randox provides a range of antioxidant reagents to assess all three levels of the body’s defence system (preventative antioxidants, scavenging antioxidants and repair enzymes).
Preventative antioxidants – inhibit the formation of free radicals including metal binding proteins like; Ceruloplasmin, Metallothionine, Albumin, Transferrin, Ferritin and Myoglobin.
Repair enzymes – repair damaged biomolecules such as DNA repair enzymes.
Scavenging antioxidants – remove any reactive species once formed such as Superoxide Dismutase, Glutathione Peroxidase, Catalase and small molecules including Ascorbate, Tocopherol, Bilirubin, Uric Acid, Carotenoids and Flavonoids.
Antioxidant benefits against disease
Free radicals have been found to play a role in the development of many diseases including cancer (free radicals are thought to promote cell transformation into a cancer cell), arthritis and inflammatory diseases (increased oxidative stress in rheumatoid arthritis patients suggests antioxidants could have an important role), cardiovascular disease (antioxidants have been found to improve cardiac health), and Alzheimer’s disease (antioxidants have a role in removing deleterious free radicals from the brain).
Reagent | Amylase
Key Benefits of the Randox Amylase reagent
Wide measuring range – The healthy range for amylase is 30 – 100 U/l. The Randox reagent can comfortably detect levels outside of this range measuring between 7.3 – 1245 µmol/l.
Excellent stability – Stable to expiry when stored at +2 to +8°C
Methodology – Ethylidene PNPG7 method
Liquid ready-to-use reagents – The Randox reagent comes in a liquid ready-to-use format which is more convenient as the reagent does not need to be reconstituted which aids in reducing the risk of errors occurring
|AY3805||R1 4 x 16ml (L)|
R2 4 x 5ml (L)
|Enquire||Kit Insert Request||MSDS||Buy Online|
|AY7931||R1 6 x 50ml (L)|
R2 4 x 18ml
|Enquire||Kit Insert Request||MSDS||Buy Online|
|AY1580||20 x 5ml||Enquire||Kit Insert Request||MSDS||Buy Online|
|AY8004||R1 7 x 18ml (L)|
R2 7 x 7.3ml
|Enquire||Kit Insert Request||MSDS||Buy Online|
|AY8335||R1 4 x 20ml (L)|
R2 4 x 7ml
|Enquire||Kit Insert Request||MSDS||Buy Online|
|(L) Indicates liquid option|
What is Amylase used for?
It is a digestive enzyme / special protein produced by the pancreas and salivary glands. Salivary amylase is responsible for breaking down starch in the mouth and converting it into maltose. Pancreatic amylase passes through a duct from the pancreas to the small intestine where the digestive process is completed through converting starch into glucose. The glucose is then absorbed into the blood and carried throughout the body.
Damage or inflammation to the pancreas can result in under / over production of amylase which can be a sign of pancreatic disorder which includes pancreatic pseudocyst, pancreatic abscess, pancreatic cancer, gallbladder disease, mumps or ectopic pregnancy. For more information on pancreatic cancer, please click here. The Randox assay is used for the quantitative in vitro determination of amylase activity in serum, urine and plasma.
Reagent | Lipase
Key Benefits of the Randox Lipase Assay
The Randox lipase assay displayed a precision of <5% CV.
The Randox lipase assay displayed an exceptional correlation coefficient of r=1.00 when compared against other commercially available methods.
Fully automated protocols
Fully automated protocols are available for a variety of clinical chemistry analysers.
Further Benefits of the Randox Lipase Assay
Liquid ready-to-use format for convenience and ease-of-use.
Measuring range of 2.0 – 744U/l for the comfortable detection of abnormal levels.
Applications available detailing instrument-specific settings for the convenient use of the Randox lipase assay on a wide range of clinical chemistry analysers.
About Lipase Testing
Elevated lipase concentrations 3-to-4-fold greater than the upper normal limit is indicative of pancreatitis, however, the degree of elevations does not correlate with the severity of the disease 2, 3.
In pancreatic dysfunction, lipase concentrations rise between 4 and 6 hours, peaking at 48 hours and returning to baseline within 8 to 14 days. It has a half-life of 6.7 to 13.7 hours in plasma. The half-life of amylase (another assay utilised in the diagnosis of pancreatic dysfunction) is less, however, lipase is filtered by the glomerulus and reabsorbed by the tubules which may contribute towards the longer half-life of lipase.
Lipase offers a few advantages over amylase including: a slightly better specificity, greater sensitivity for patients presenting late, due to the longer half-life, and greater sensitivity in alcoholic pancreatitis 4.
Furthermore, for prolonged longitudinal injuries, lipase activity tends to be more sensitive compared to amylase as lipase concentrations within the zymogen granules are approximately 4.5 times than those of amylase. Consequently, recurring injuries are more likely to be recognised due to the leakage of lipase into the bloodstream. Moreover, lipase concentrations are less affected by intestinal injury or renal dysfunction compared to amylase 2.
Derived from zymogen granules of pancreatic acinar cells, lipase is involved in the digestion of lipids for the subsequent absorption in the small intestine 1, 2. The pancreas is located in the anterior abdominal cavity adjacent to the liver, duodenum and stomach to allow the secretion of digestive enzymes into the small intestine, and to convert ingesta into absorbable lipids, carbohydrates and proteins. The exocrine pancreas provides a microenvironment for pancreatic islet cells. The pancreatic islet cells provide the embedded endocrine function of the pancreas which in turn enables the hepatic and peripheral tissues to modulate blood glucose levels and other functions 2.
Featured Reagent | G6PDH
Glucose-6-phosphate dehydorgenase (G6PDH/G6PD) deficiency is an x-linked and sex-linked metabolic disorder, commonly affecting men more so than women1. The G6PDH enzyme is critical for the proper functioning of red blood cells (RBC’s). Depleated levels of G6PDH can cause the premature destruction of RBC’s (haemolysis). If the bone marrow cannot compensate for the reduction in RBC’s, heamolyic anaemia can develop. It is important to note that a deficiency in the G6PDH enzyme is not enough to promote the onset of haemolysis, but rather additional factors are required to promote the onset of symptoms2.
Some of the common side effects of G6PDH deficiency include: paleness, dark urine, yellowing of the skin and whites of the eyes, a rapid heart rate and shortness of breath. Common triggers for the development of haemolytic anaemia in those who are G6PDH deficient include: bacterial and viral infections, certain drugs (medications and antibiotics to treat malaria), and favism (inhaling the pollen from fava plants and ingesting fava beans)3
G6PDH deficiency has been recognised as a significant cause of mild to severe jaundice in newborns. It has been noted that those with this disorder commonly will not experience any signs or symptoms making them unaware that they have the condition3.
Haemolytic anaemia is an umbrella term used to describe the premature destruction of red blood cells (RBC’s). This disorder encompasses numerous conditions including: autoantibodies, medications, underlying malignancy, bone marrow failure, infection and heredity conditions including sickle cell disease or haemoglobinopathies4 5.
The severity of haemolytic anaemia depends on whether the onset of haemolysis is gradual or rapid and on the extent of RBC destruction. Patients with mild haemolysis can be asymptomatic whereas the anaemia in severe haemolysis can be life-threatening and can cause angina and cardiopulmonary decompensation. Haemolytic anaemia is an intravascular phenomenon meaning that this type of haemolysis occurs within the blood vessels and is caused by the following conditions: prosthetic cardiac valves, glucose-6-phosphate dehydrogenase (G6PDH) deficiency, thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, transfusion of ABO incompatible blood and paroxysmal nocturnal haemoglobinuria (PNH)6.
Heredity disorders can also cause haemolysis due to the erythrocyte membrane and haemoglobin abnormalities, and enzymatic defects. Some hereditary disorders include: G6PDH deficiency, hereditary spherocytosis and sickle cell anaemia6.
Glucose-6-phosphate dehydrogenase (G6PDH) is a cytosolic enzyme located on the X-chromosome found in bodily cells. G6PDH is involved in the normal processing of carbohydrates and plays a critical role in RBC, protecting them from damage and premature destruction. The two main products of G6PDH are ribose-5-phosphate which is important for DNA, the chemical cousin of RNA. The chemical reaction produces NADPH which protects bodily cells from reactive oxygen species1.
Benefits of the G6PDH Assay
A niche assay from Randox meaning that Randox are one of the only manufacturers to offer a G6PDH assay in an automated biochemistry format.
Superior stability of 4 weeks upon reconstitution and stored at +2°C to +8°C. Many other commercially available assays offer only 5 days stability, leading to product wastage.
Minimal interference as the sample pre-wash step included in the Randox G6PDH testing method serves to purify the sample, leading to no known interferences being observed.
Excellent correlation coefficient of r=0.99 when compared against other commercially available methods.
Lyophilised reagent for enhanced stability.
G6PDH controls offering a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox G6PDH assay on a wide range of clinical chemistry analsyers.
 Croom, Edward. Progress in Molecular Biology and Translational Science. 2012. ISBN 9780124158139 / ISSN 1877-1173.
 National Organization for Rare Disorders. Glucose-6-Phosphate Dehydrogenase Deficiency. [Online] no date. [Cited: January 31, 2019.] https://rarediseases.org/rare-diseases/glucose-6-phosphate-dehydrogenase-deficiency.
 U.S. National Library of Medicine. Glucose-6-phosphate dehydrogenase deficiency. [Online] May 2017. [Cited: January 30, 2019.] https://ghr.nlm.nih.gov/condition/glucose-6-phosphate-dehydrogenase-deficiency.
 National Heart, Lung, and Blood Institute. Hemolytic Anemia. [Online] no date. [Cited: January 28, 2019.] https://www.nhlbi.nih.gov/health-topics/hemolytic-anemia.
 BMJ Publishing Group. Hemolytic anemia. BMJ Best Practice. [Online] March 2018. [Cited: January 28, 2019.] https://bestpractice.bmj.com/topics/en-us/98.
 Schick, Paul. Hemolytic Anemia. Medscape. [Online] December 29, 2018. [Cited: Janaury 28, 2018.] https://emedicine.medscape.com/article/201066-overview.
MORE FEATURED REAGENTS
Read more about the Randox range of assays